Showing 1 - 20 results of 55 for search '"ингаляционные кортикостероиды"', query time: 0.70s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
    Academic Journal
  5. 5
    Academic Journal

    Source: Meditsinskiy sovet = Medical Council; № 20 (2024); 24-28 ; Медицинский Совет; № 20 (2024); 24-28 ; 2658-5790 ; 2079-701X

    File Description: application/pdf

    Relation: https://www.med-sovet.pro/jour/article/view/8754/7687; Cunha AS, Raposo B, Dias F, Henriques S, Martinho H, Pedro AR. Management of Chronic Obstructive Pulmonary Disease: Constraints in Patient Pathway and Mitigation Strategies. Port J Public Health. 2024;12:1-8. https://doi.org/10.1159/000535474.; Самородская ИВ, Болотова ЕВ, Дудникова АВ. Динамика и структура смертности от болезней органов дыхания и COVID-19 в Российской Федерации за 2019-2021 гг. Клиническая медицина. 2022;100(11-12):535-539. https://doi.org/10.30629/0023-2149-2022-100-11-12-535-539.; Koopman M, Posthuma R, Vanfleteren LEGW, Simons SO, Franssen FME. Lung Hyperinflation as Treatable Trait in Chronic Obstructive Pulmonary Disease: A Narrative Review. Int J Chron Obstruct Pulmon Dis. 2024;19:1561-1578. https://doi.org/10.2147/COPD.S458324.; Cazzola M, Rogliani P, Laitano R, Calzetta L, Matera MG. Beyond Dual bronchodilation - Triple Therapy, When and Why. Int J Chron Obstruct Pulmon Dis. 2022;17:165-180. https://doi.org/10.2147/COPD.S345263.; Болотова ЕВ, Дудникова АВ, Шульженко ЛВ. Опыт применения тройной фиксированной комбинации в лечении больных хронической обструктивной болезнью легких. Терапевтический архив. 2022;94(3):396-400. https://doi.org/10.26442/00403660.2022.03.201406.; Авдеев СН, Айсанов ЗР, Ардашева ТВ, Белевский АС, Демко ИВ, Зайцев АА и др. Хроническая обструктивная болезнь легких: клинические рекомендации. 2023 г. Режим доступа: https://spulmo.ru/upload/kr/HOBL_2023_draft.pdf.; Malerba M, Foci V, Patrucco F, Pochetti P, Nardin M, Pelaia C, Radaeli A. Single Inhaler LABA/LAMA for COPD. Front Pharmacol. 2019;10:390. https://doi.org/10.3389/fphar.2019.00390.; Melani AS, Croce S, Fabbri G, Messina M, Bargagli E. Inhaled Corticosteroids in Subjects with Chronic Obstructive Pulmonary Disease: An Old, Unfinished History. Biomolecules. 2024;14(2):195. https://doi.org/10.3390/biom14020195.; Авдеев СН, Лещенко ИВ, Айсанов ЗР, Архипов ВВ, Белевский АС, Овчаренко СИ и др. Новые клинические рекомендации по ХОБЛ - смена парадигмы. Терапевтический архив. 2024;96(3):292-297. https://doi.org/10.26442/00403660.2024.03.202646.; Banerji D, Fogel R, Patalano F. Indacaterol/glycopyrronium: a dual bron-chodilator for COPD. Drug Discov Today. 2018;23(1):196-203. https://doi.org/10.1016/j.drudis.2017.10.015.; Frampton JE. QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease. Drugs. 2014;74(4):465-488. https://doi.org/10.1007/s40265-014-0194-8.; Sanders MJ. Guiding Inspiratory Flow: Development of the In-Check DIAL G16, a Tool for Improving Inhaler Technique. Pulm Med. 2017;2017:1495867. https://doi.org/10.1155/2017/1495867.; Dolovich MB, Kuttler A, Dimke TJ, Usmani OS. Biophysical model to predict lung delivery from a dual bronchodilator dry-powder inhaler. Int J Pharm X. 2019;1:100018. https://doi.org/10.1016/j.ijpx.2019.100018.

  6. 6
    Academic Journal

    Source: Meditsinskiy sovet = Medical Council; № 20 (2023); 28-35 ; Медицинский Совет; № 20 (2023); 28-35 ; 2658-5790 ; 2079-701X

    File Description: application/pdf

    Relation: https://www.med-sovet.pro/jour/article/view/7883/6997; Johnson M, Rennard S. Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD. Chest. 2001;120(1):258–270. https://doi.org/10.1378/chest.120.1.258.; Paggiaro PL, Giannini D, Di Franco A, Testi R. Comparison of inhaled salmeterol and individually dose-titrated slow-release theophylline in patients with reversible airway obstruction. European Study Group. Eur Respir J. 1996;9(8):1689–1695. https://doi.org/10.1183/09031936.96.09081689.; Perera BJ. Salmeterol multicentre asthma research trial (SMART): interim analysis shows increased risk of asthma related deaths. Ceylon Med J. 2003;48(3):99. https://doi.org/10.4038/cmj.v48i3.3362.; Williams C. Cause of death in the SMART Trial. Chest. 2006;130(3):929–930. https://doi.org/10.1378/chest.130.3.929-a.; Визель АА, Визель ИЮ. Хроническая обструктивная болезнь легких – от истоков к современности (исторический обзор литературы). Туберкулез и болезни легких. 2019;97(2):42–49. https://doi.org/10.21292/2075-1230-2019-97-2-42-49.; Чучалин АГ, Авдеев СН, Айсанов ЗР, Белевский АС, Васильева ОС, Геппе НА и др. Бронхиальная астма: федеральные клинические рекомендации по диагностике и лечению. Пульмонология. 2022;32(3):393–447. https://doi.org/10.18093/0869-0189-2022-32-3-393-447.; Reddel HK, Bateman ED, Schatz M, Krishnan JA, Cloutier MM. A Practical guide to implementing SMART in asthma management. J Allergy Clin Immunol Pract. 2022;10(1 Suppl.):31–38. https://doi.org/10.1016/j.jaip.2021.10.011.; Ненашева НМ. Концепция «противовоспалительный бронхолитик»: гармония между потребностями пациента и целями врача при бронхиальной астме любой степени тяжести. Практическая аллергология. 2021;(1):8–16. https://doi.org/10.46393/2712-9667_2021_1_8-16.; Демко ИВ, Мамаева МГ, Собко ЕА, Крапошина АЮ, Гордеева НВ. Клинический опыт применения будесонида/формотерола у пациентов с хронической обструктивной болезнью легких. Медицинский совет. 2021;(16):26–31. https://doi.org/10.21518/2079-701X-2021-16-26-31.; Aryani T, Rahmawati RK, Cintyadewi NP, Puspitasari AD, Rasyid AN, Samirah. Patterns of bronchodilator therapy in asthmatic outpatients. J Public Health Afr. 2023;14(Suppl. 1):2533. https://doi.org/10.4081/jphia.2023.2533.; Vinnikov D, Raushanova A, Mukatova I, Nurpeissov T, Кushekbayeva A, Toxarina A et al. Asthma control in Kazakhstan: need for urgent action. BMC Pulm Med. 2023;23(1):7. https://doi.org/10.1186/s12890-022-02287-2.; Nishi MK, Akter S, Tania IJ, Shams N, Khatun S. Use of Drugs considering route of administration on drug prescription pattern for bronchial asthma in a tertiary level hospital. Mymensingh Med J. 2023;32(1):73–75. Available at: https://pubmed.ncbi.nlm.nih.gov/36594304.; Salciccioli JD, Israel E. As-needed inhaled corticosteroids as add-on therapy versus SMART therapy: an evolving understanding of the two approaches in the management of moderate-to-severe asthma. Curr Opin Pulm Med. 2023;29(3):209–214. https://doi.org/10.1097/MCP.0000000000000961.; Larenas-Linnemann D, Romeo J, Ariue B, Oppenheimer J. American College of Allergy, Asthma and Immunology members’ preferred steps 1 to 3 asthma maintenance and reliever therapy and incomplete insurance coverage indicated as main practice hurdle. Ann Allergy Asthma Immunol. 2023;131(4):451–457. https://doi.org/10.1016/j.anai.2023.05.036.; Krings JG, Sekhar TC, Chen V, Blake KV, Sumino K, James AS et al. Beginning to address an implementation gap in asthma: clinicians’ views of prescribing reliever budesonide-formoterol inhalers and SMART in the United States. J Allergy Clin Immunol Pract. 20023;11(9):2767–2777. https://doi.org/10.1016/j.jaip.2023.05.023.; Janson C, Melén E, de Fine Licht S, Telg G, Maslova E, Tran TN et al. Prescribing patterns of budesonide/formoterol maintenance and reliever therapy in patients with asthma in Sweden. Allergy. 2023;78(8):2311–2314. https://doi.org/10.1111/all.15710.; Günaydın FE, Ay P, Karakaya G, Ediger D. How do we manage asthma? Assessment of knowledge, attitude, and practice patterns among pulmonologists and allergists. J Asthma. 2023;60(1):130–138. https://doi.org/10.1080/02770903.2022.2033261.; Czira A, Banks V, Requena G, Wood R, Tritton T, Wild R et al. Characterisation of patients with chronic obstructive pulmonary disease initiating single-device inhaled corticosteroids/long-acting β2 -agonist dual therapy in a primary care setting in England. BMJ Open Respir Res. 2022;9(1):e001243. https://doi.org/10.1136/bmjresp-2022-001243.; Brattsand R, Selroos O. May a different kinetic mode explain the high efficacy/safety profile of inhaled budesonide? Pulm Pharmacol Ther. 2022;77:102167. https://doi.org/10.1016/j.pupt.2022.102167.; Varacca G, D’Angelo D, Glieca S, Cavalieri L, Piraino A, Quarta E et al. The impact of possible improper use on the performance in vitro of NEXThaler in comparison with Ellipta inhaler. Eur J Pharm Sci. 2023;183:106385. https://doi.org/10.1016/j.ejps.2023.106385.; Renner A, Marth K, Breyer-Kohansal R, Pohl W. Combined analysis of five non-interventional studies of the effectiveness, tolerability, and safety of the extrafine fixed dose beclomethasone/formoterol combination in the treatment of asthma in Austria. Respir Med. 2023;207:107097. https://doi.org/10.1016/j.rmed.2022.107097.; Титова ОН, Кузубова НА, Лебедева ЕС, Преображенская ТН. Эффект применения экстрамелкодисперсной комбинации беклометазон/формотерол на ранней стадии формирования модели ХОБЛ. РМЖ. 2022;(2):16–20. Режим доступа: https://www.rmj.ru/articles/bolezni_dykhatelnykh_putey/Effekt_primeneniya_ekstramelkodispersnoy_kombinacii_beklometazonformoterol_naranney_stadii_formirovaniya_modeli_HOBL.; Метельский СМ, Давидовская ЕИ, Нагорнов ИВ, Ермолкевич РФ, Богуш ЛС, Рузанов ДЮ, Воробьева ОИ. Место ингаляционных кортикостероидных препаратов в комплексной терапии ХОБЛ с позиций GOLD-2022. Рецепт. 2022;25(5):660–673. https://doi.org/10.34883/PI.2022.25.5.009.; Bakakos P, Chatziapostolou P, Katerelos P, Efstathopoulos P, Korkontzelou A, Katsaounou P. Extrafine beclometasone dipropionate/formoterol nexthaler on device usability, adherence, asthma control and quality of life. A panhellenic prospective, non-interventional observational study in patients with asthma-the NEXT-Step Study. J Pers Med. 2022;12(2):146. https://doi.org/10.3390/jpm12020146.; Luo Z, Lucci G, Santoro L, Topole E, Mariotti F. Pharmacokinetic profile of beclometasone dipropionate/formoterol fumarate administered through a novel dry-powder inhaler in Chinese healthy volunteers. Pulm Pharmacol Ther. 2022;73–74:102129. https://doi.org/10.1016/j.pupt.2022.102129.; Reddel HK, Brusselle G, Lamarca R, Gustafson P, Anderson GP, Jorup C. Safety and effectiveness of as-needed formoterol in asthma patients taking inhaled corticosteroid (ics)-formoterol or ics-salmeterol maintenance therapy. J Allergy Clin Immunol Pract. 2023;11(7):2104-2114.e3. https://doi.org/10.1016/j.jaip.2023.03.046.; Muiser S, Imkamp K, Seigers D, Halbersma NJ, Vonk JM, Luijk BHD et al. Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD. Thorax. 2023;78(5):451–458. https://doi.org/10.1136/thorax-2022-219620.; Price DB, Henley W, Cançado JED, Fabbri LM, Kerstjens HAM, Papi A et al. Interclass difference in pneumonia risk in copd patients initiating fixed dose inhaled treatment containing extrafine particle beclometasone versus fine particle fluticasone. Int J Chron Obstruct Pulmon Dis. 2022;17:355–370. https://doi.org/10.2147/COPD.S342357.; Jiang T, Li P, Wang Y. Effect of budesonide formoterol combined with tiotropium bromide on pulmonary function and inflammatory factors in patients with asthma-COPD overlap syndrome. Allergol Immunopathol (Madr). 2023;51(4):131–138. https://doi.org/10.15586/aei.v51i4.876.; Samajdar SS, Mukherjee S, Moitra S, Pal J, Joshi S, Tripathi SK. Effectiveness of budesonide formoterol fixed-dose combination MDI in reducing cough symptoms in COVID-19 patients: A real-world evidence study. Lung India. 2023;40(2):107–111. https://doi.org/10.4103/lungindia.lungindia_268_22.; van der Veer T, de Koning Gans JM, Braunstahl GJ, Pieters ALP, van den Berg JMW, Hoek RAS et al. The effect of beclomethasone-formoterol versus placebo on chronic cough in patients with non-CF bronchiectasis: the FORZA randomised controlled trial. Eur Respir J. 2023;61(6):2300186. https://doi.org/10.1183/13993003.00186-2023.; Maneechotesuwan K, Singh D, Fritscher LG, Dursunoglu NPGA, Phansalkar A, Aggarwal B et al. Impact of inhaled fluticasone propionate/salmeterol on health-related quality of life in asthma: A network meta-analysis. Respir Med. 2022;203:106993. https://doi.org/10.1016/j.rmed.2022.106993.; Hale EM, Greene G, Mulvey C, Mokoka MC, van Boven JFM, Cushen B et al.; INCA Research Team. Use of digital measurement of medication adherence and lung function to guide the management of uncontrolled asthma (INCA Sun): a multicentre, single-blinded, randomised clinical trial. Lancet Respir Med. 2023;11(7):591–601. https://doi.org/10.1016/S2213-2600(22)00534-3.; Doniec Z, Olszanecka-Glinianowicz M, Hantulik P, Almgren-Rachtan A, Chudek J. The assessment of effectiveness, tolerance, and patient satisfaction with the use of a new fixed-dose combination product, containing salmeterol and fluticasone propionate, Salflumix Easyhaler® in the treatment of asthma in the daily clinical practice. J Asthma. 2023;60(4):754–760. https://doi.org/10.1080/02770903.2022.2093220.; Feldman WB, Kesselheim AS, Avorn J, Russo M, Wang SV. Comparative effectiveness and safety of generic versus brand-name fluticasonesalmeterol to treat chronic obstructive pulmonary disease. Ann Intern Med. 2023;176(8):1047–1056. https://doi.org/10.7326/M23-0615.; Alyami MH, Dahmash EZ, Ali DK, Alyami HS, AbdulKarim H, Alsudir SA. Novel fluticasone propionate and salmeterol fixed-dose combination nano-encapsulated particles using polyamide based on L-Lysine. Pharmaceuticals (Basel). 2022;15(3):321. https://doi.org/10.3390/ph15030321.; Mills H, Acquah R, Tang N, Cheung L, Klenk S, Glassen R et al. Biochemical behaviours of salmeterol/fluticasone propionate in treating asthma and chronic obstructive pulmonary diseases (COPD). Emerg Med Int. 2022;2022:2593740. https://doi.org/10.1155/2022/2593740.

  7. 7
  8. 8
    Academic Journal
  9. 9
    Academic Journal

    Source: Буковинський медичний вісник; Том 25 № 2(98) (2021); 135-140
    Буковинский медицинский вестник; Том 25 № 2(98) (2021); 135-140
    Bukovinian Medical Herald; Vol. 25 No. 2(98) (2021); 135-140

    File Description: application/pdf

  10. 10
  11. 11
  12. 12
    Academic Journal

    Authors: Korenyuk, О. S.

    Source: Actual Problems of Pediatry, Obstetrics and Gynecology; No. 2 (2014) ; Актуальные вопросы педиатрии, акушерства и гинекологии; № 2 (2014) ; Актуальні питання педіатрії, акушерства та гінекології; № 2 (2014) ; 2415-301X ; 2411-4944 ; 10.11603/24116-4944.2014.2

    File Description: application/pdf

  13. 13
  14. 14
    Academic Journal

    Source: Zaporozhye Medical Journal; Vol. 21 No. 2 (2019) ; Запорожский медицинский журнал; Том 21 № 2 (2019) ; Запорізький медичний журнал; Том 21 № 2 (2019) ; 2310-1210 ; 2306-4145

    File Description: application/pdf

  15. 15
    Academic Journal

    File Description: application/pdf

    Relation: Ємельянова Н. Ю. Клінічні показники стоматологічного статусу хворих із хронічними обструктивними захворюваннями легень / Н. Ю. Ємельянова // Український стоматологічний альманах. ‒ 2018. ‒ № 3. ‒ С. 5–10.; https://repository.pdmu.edu.ua/handle/123456789/10169

  16. 16
    Academic Journal

    Source: Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice; № 1 (2013); 47-49 ; Качественная клиническая практика; № 1 (2013); 47-49 ; 2618-8473 ; 2588-0519

    File Description: application/pdf

    Relation: https://www.clinvest.ru/jour/article/view/170/172; Bateman E., Hurd S. Barnes P., et al. Global strategy for asthma management and prevention: GINA executive summary // Eur. Respir. J. 2008; 31: 143—178.; Открытое проспективное наблюдательное исследование эффективности и безопасности свободной комбинации Форадила Аэролайзера и ингаляционного глюкокортикостероида у больных с бронхиальной астмой. Протокол CFOR258DRU01. Статистический отчёт.; Nave R., Mueller H. From inhaler to lung: clinical implications of the formulations of ciclesonide and other inhaled corticosteroids International Journal of General Medicine 2013:6 99—107.; Manning P., Gibson P.G., Lasserson T.J. Ciclesonide versus other inhaled steroids for chronic asthma in children and adults // Cochrane Database Syst. Rev. 2008; (2): CD007031.; Айсанов З.Р., Калманова Е.Н., Стулова О.Ю. Циклесонид (Альвеско®) в лечении больных бронхиальной астмой // РМЖ 2012; 6: 341-344.; Williams L.K., Pladevall M., Xi H., et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma // J. Allergy Clin. Immunol. 2004; 114(6): 1288-93.; Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance // Clin. Ther. 2001; 23(8): 1296-310.; Price D., Robertson A., Bullen K., et al. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study // BMC Pulm. Med. 2010; 10: 1.; Friedman H.S., Urdaneta E., McLaughlin J.M., Navaratnam P. Mometasone furoate versus beclomethasone dipropionate: eff ectiveness in patients with mild asthma // Am. J. Manag. Care 2010; 16(7): e151-6.; Williams L.K., Peterson E.L., Wells K., et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence // J. Allergy Clin. Immunol. 2011; 128(6): 1185-1191.e2.; Авксентьева М.В., Ильина Н.И., Лазарева Н.Б., Омельяновский В.В. Социально-экономическое бремя бронхиальной астмы и хронической обструктивной болезни легких в Российской Федерации, М., 2010.; https://www.clinvest.ru/jour/article/view/170

  17. 17
  18. 18
  19. 19
  20. 20